A Phase 1b Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 4 Weeks Treatment With BAY 2413555 in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices
Latest Information Update: 14 Mar 2024
At a glance
- Drugs BAY 2413555 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Acronyms REMOTE-HF
- Sponsors Bayer
Most Recent Events
- 05 May 2023 Status changed from recruiting to discontinued due to new preclinical findings in a chronic toxicology study.
- 17 Oct 2022 Status changed from not yet recruiting to recruiting.
- 16 Sep 2022 New trial record